Rockville, MD – In a recent transaction, Padmanabh P. Bhatt, Sr. VP of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), sold 12,364 shares of the company's common stock, netting a total of $436,572. The shares were sold at prices ranging from $35.30 to $35.34, with the reported weighted average price being $35.31. This sale was conducted in accordance with a 10b5-1 trading plan, which was adopted on September 7, 2023.
On the same day, Bhatt also acquired 12,364 shares of Supernus Pharmaceuticals through the exercise of options, with the exercise price set at $25.30 per share, amounting to a total transaction value of $312,809. The options had vested in four equal annual installments beginning on February 24, 2018, and are set to expire on February 24, 2027.
Following these transactions, Bhatt's direct ownership in the company's common stock has been adjusted to 8,570 shares. The company, headquartered at 9715 Key West Avenue in Rockville, Maryland, specializes in pharmaceutical preparations and is known for its commitment to developing and commercializing products to treat central nervous system diseases.
Investors and followers of Supernus Pharmaceuticals can obtain full information regarding the number of shares sold at each separate price within the reported range by reaching out to the company or the Securities and Exchange Commission, as per Bhatt's undertaking.
These transactions reflect the ongoing financial activities of the company's executives and provide insight into their investment decisions regarding company stock. Supernus Pharmaceuticals continues to be a key player in the pharmaceutical industry, with ongoing developments and contributions to the field of neuroscience.
InvestingPro Insights
Amid the recent insider trading activity at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), investors may be interested in the broader financial landscape of the company. According to InvestingPro data, Supernus Pharmaceuticals holds a market capitalization of approximately $1.93 billion. The company's P/E ratio, based on the last twelve months as of Q4 2023, stands at a high 117.09, which might indicate that the stock is trading at a premium compared to its earnings. Despite a slight decline in revenue growth of -8.95% over the same period, the company maintains a robust gross profit margin of 86.21%.
InvestingPro Tips highlight that Supernus Pharmaceuticals holds more cash than debt on its balance sheet, which is a positive sign of financial stability. Additionally, the company is expected to be profitable this year, with net income projected to grow. This is further supported by the fact that two analysts have revised their earnings expectations upwards for the upcoming period. For investors considering the long-term performance, it's worth noting that the company has experienced a high return over the last decade.
For those interested in further insights and metrics on Supernus Pharmaceuticals, InvestingPro offers additional tips that could help in making more informed investment decisions. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 12 more InvestingPro Tips available for Supernus Pharmaceuticals, which can be accessed at: https://www.investing.com/pro/SUPN
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.